Conversion From Calcineurin Inhibitors to Belatacept in HLA-sensitized Kidney Transplant Recipients With Low-level Donor-specific Antibodies
Gestores bibliográficos
Compartir
item.contributor.advisor
ORCID:
Journal Title
Journal ISSN
Volume Title
Publisher
item.page.isbn
item.page.issn
item.page.issne
item.page.doiurl
item.page.extent
item.page.accessRights
item.page.other
item.page.references
Abstract
Background: Belatacept could be the treatment of choice in renal-transplant recipients with renal dysfunction attributed to calcineurin inhibitor (CNI) nephrotoxicity. Few studies have described its u...
Description
item.page.coverage.spatial
item.page.sponsorship
Citation
Ulloa CE, Anglicheau D, Snanoudj R, Scemla A, Martinez F, Timsit MO, Legendre C, Sberro-Soussan R. Conversion From Calcineurin Inhibitors to Belatacept in HLA-sensitized Kidney Transplant Recipients With Low-level Donor-specific Antibodies. Transplantation. 2019 Oct;103(10):2150-2156. doi:10.1097/TP.0000000000002592.
Keywords
Abatacept / administration & dosage , Calcineurin Inhibitors / administration & dosage , Calcineurin Inhibitors / adverse effects , Drug Substitution , Allografts / drug effects , Calcineurin Inhibitors / adverse effects , Glomerular Filtration Rate / drug effects , Glomerular Filtration Rate / immunology , Graft Rejection / drug therapy , Graft Rejection / immunology , Graft Rejection / pathology , HLA Antigens / immunology , Isoantibodies / blood , Isoantibodies / immunology , Isoantigens / immunology , Kidney / drug effects , Kidney / immunology , Kidney Transplantation / adverse effects , Renal Insufficiency / chemically induced , Renal Insufficiency / prevention & control
item.page.dc.rights
item.page.dc.rights.url
Estadísticas de uso
1 0,8 0,5 0,3 0
Agosto 2025Septiembre 2025Octubre 2025Noviembre 2025Diciembre 2025Enero 2026Febrero 2026